Healthcare Most Active Stocks: Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Teva Pharmaceutical Industries (NYSE:TEVA), Bristol-Myers Squibb (NYSE:BMY)

During the trial, palbociclib — a pill — was combined with the standard anti-estrogen treatment Letrozole. The combined treatment resulted in a 26.1 month progression-free survival rate compared with only 7.5 months for Letrozole alone. Under development by Pfizer Inc. (NYSE:PFE), the medication used in the study is a selective inhibitor of cyclin-dependent kinases (CDK) 4 and 6. Pfizer Inc. (NYSE:PFE) stock performance was -1.06% in last session and finished the day at $30.87. Traded volume was 34.57million shares in the last session and the average volume of the stock remained 27.71million shares. The beta of the stock remained 0.64. Pfizer Inc. (NYSE:PFE) insider ownership is 0.10%.

Express Scripts Holding Co., a pharmacy benefits manager that handles more than 1 billion prescriptions a year in the U.S., is ratcheting up its effort to force Gilead Sciences Inc. (NASDAQ:GILD) to cut the $84,000 price of its new hepatitis C pill Sovaldi. Gilead Sciences, Inc. (NASDAQ:GILD) dropped -3.07 percent to $70.01 Tuesday on volume of 25.27million shares. The intra-day range of the stock was $69.28 to $71.71. Gilead Sciences, Inc. (NASDAQ:GILD) has a market capitalization of $107.67billion.

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) said Tuesday it is now selling a generic version of the heart medication Lovaza, which is used to treat high triglyceride levels. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)’s stock on Apr 08, 2014 reported a decrease of -1.18% to the closing price of $50.90. Its fifty two weeks range is $36.26 -$54.70. The total market capitalization recorded $48.31billion. The overall volume in the last trading session was 12.30million shares. In its share capital, TEVA has 955.87million outstanding shares.

Scientists from Bristol-Myers Squibb Co (NYSE:BMY) have developed a novel approach for the simultaneous quantitation of neutralizing antibodies, residual drug, and human Immunoglobulin G (IgG) in immunogenicity assay development using liquid chromatography–tandem mass spectrometry (LC–MS–MS). On Tuesday, shares of Bristol-Myers Squibb Co (NYSE:BMY) dropped -2.43% to close the day at $49.06. Company return on investment (ROI) is 10.70% and its monthly performance is recorded as -12.00%. Bristol-Myers Squibb Co (NYSE:BMY) quarterly revenue growth is -6.02%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone